December 29, 2017 / 12:08 PM / 6 months ago

BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018

Dec 29 (Reuters) - Ignyta Inc:

* IGNYTA REPORTS FDA CLEARANCE OF IND FOR RXDX-106, A NOVEL IMMUNOMODULATORY AGENT AND TYRO3, AXL, MER (TAM) INHIBITOR

* IGNYTA INC - COMMENCING PHASE 1 STUDY FOR RXDX-106 IN EARLY 2018

* IGNYTA INC - UNDER IND, CO INTENDS TO INITIATE TARGETED IMMUNOMODULATORY TAM ANTAGONIST STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below